NCT07215559 · Eli Lilly and Company
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
What this study is about
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
View original scientific description
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Have type 2 diabetes
- Have an HbA1c ≥7.5% to ≤10.5% at screening
- Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening
- Diet and exercise
- Stable dose of metformin
- Sodium-glucose cotransporter-2 (SGLT2) inhibitor
- Have had a stable body weight (\<5% body weight gain and/or loss) for the 3 months prior to screening
- Have a BMI of 27 or greater at screening
Exclusion criteria
- Have any form of diabetes other than type 2 diabetes
- Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening
- Have any of the following cardiovascular conditions within 3 months prior to screening:
- acute myocardial infarction
- cerebrovascular accident (stroke)
- unstable angina, or
- hospitalization due to congestive heart failure
- Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include
- basal or squamous cell skin cancer
- in situ carcinomas of the cervix, or
- in situ prostate cancer
- Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months:
- dual amylin and calcitonin RA
- glucagon-like peptide-1 receptor (GLP-1) RA
- glucose-dependent insulinotropic peptide (GIP)/GLP-1 RA
- GLP-1/glucagon (GCG) RAs, or
- GIP/GLP-1/GCG RAs
- Have used excluded antihyperglycemic medications within 3 months prior to screening (including, but not limited to, sulfonylureas, dipeptidyl peptidase-4 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinides
- Have used insulin for diabetic control within the prior year (short term use in certain situations allowed
Where
- Gilbert, Arizona
- Phoenix, Arizona
- Tucson, Arizona
- Sunrise, Florida
- Atlanta, Georgia
- Lawrenceville, Georgia
- Sandy Springs, Georgia
- Stonecrest, Georgia
- Union City, Georgia
- Las Vegas, Nevada
- Trenton, New Jersey
- Dayton, Ohio
And 11 more locations — see the full list below.
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jul 7, 2026 · Source of record for eligibility and locations